N
MRVI icon

Natixis’s Maravai LifeSciences MRVI Stock Holding History

Natixis’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-27,423
Closed -$180K – 1149
2023
Q4 		$180K Sell
27,423
-380,685
-93% -$2.46M ﹤0.01% 725
2023
Q3 		$4.08M Sell
408,108
-1,394,035
-77% -$15.3M 0.03% 310
2023
Q2 		$22.4M Buy
1,802,143
+1,489,716
+477% +$20.1M 0.18% 116
2023
Q1 		$4.38M Buy
+312,427
New +$4.49M 0.04% 290
2022
Q2 		– Sell
-1,000,000
Closed -$35.3M – 1278
2022
Q1 		$35.3M Buy
+1,000,000
New +$33.5M 0.12% 173

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Natixis's MRVI Position: Q1 2024 in Review

Natixis sold out of Maravai LifeSciences (MRVI) in Q1 2024, closing a stake of 27,423 shares — an estimated $180K sold.

Natixis first reported a position in MRVI in Q1 2022 and held it in 5 quarters. The position peaked at $35.3M in Q1 2022. 210 funds tracked by Wall St. Rank hold MRVI as of Q1 2024.

  • Natixis reported no remaining Maravai LifeSciences position as of Q1 2024 after selling out during the quarter.
  • Natixis sold 27,423 Maravai LifeSciences shares in Q1 2024, an estimated $180K.
  • Natixis first reported a position in Maravai LifeSciences in Q1 2022 and held it in 5 quarters.
  • Natixis's Maravai LifeSciences position peaked at $35.3M in Q1 2022.
  • 210 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2024.

Based on Natixis's 13F filing for Q1 2024, filed 13 May 2024.